AAX Biotech and evitria Partner to Expand Access to Opti-mAb® Technology

STOCKHOLM, April 23, 2026 – AAX Biotech, a leading innovator in technologies for antibody-based therapies, has announced a significant partnership with evitria AG. evitria, an expert provider of antibody engineering and expression services, will now offer its clientele access to AAX Biotech's proprietary Opti-mAb® technology, integrating it into early antibody development workflows.

The Opti-mAb® technology is specifically designed to address a persistent obstacle in antibody engineering: the instability of single-chain variable fragments (scFv). By improving stability and developability, Opti-mAb® facilitates the creation of more robust antibody therapeutics, thereby enhancing expression and downstream development processes.

Under the terms of the agreement, evitria will provide access to Opti-mAb® under a research license. The technology may also be incorporated into multispecific antibody formats during early-stage evaluation, tailored to customer needs and project requirements. Daniel X Johansson, CEO and CSO of AAX Biotech, highlighted the strategic importance of this integration, stating, "Integrating Opti-mAb® early in the antibody discovery and development process allows us to address key challenges already at the design stage and support the selection of more developable antibody candidates."

This partnership not only extends the reach of Opti-mAb® across a wider range of antibody discovery programs but also underscores bother companies' commitment to innovation. Stefan Schmidt, Group Chief Scientific Officer at Atlas Antibodies and scientific lead at evitria, emphasized that offering Opti-mAb® access strengthens evitria's ability to deliver complex antibody formats and support customers in selecting high-quality molecules with improved stability and expression.